@inproceedings{inproceedings, title  = {{SOGUG-NEOWIN: A phase 2, open-label, multicenter, multinational interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and the combination of ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) harboring FGFR gene alterations.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{https://doi.org/10.1200/jco.2025.43.16_suppl.tps4628 }},

 year = {{2025}},

 month = {{6}},

 author = {{de Velasco G and Necchi A and Loriot Y and Hussain SA}},

 doi = {{10.1200/jco.2025.43.16_suppl.tps4628}},

 volume = {{43}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{16_suppl}},

 note = {{Accessed on 2025/12/05}}}